Gyre Therapeutics, Inc. Share Price & Technical Analysis
GYRE · $5.96 (-1.65%)
Healthcare / Biotechnology
$5.96
-1.65%
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the…
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
-21% return in May, -12% avg return in past 3 year May month.
-10% return in 2026, 59% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 14% | 3% | -15% | 8% | -21% | – | – | – | – | – | – | – | -10% |
| 25 | -6% | 2% | -34% | 20% | -7% | -20% | -3% | 10% | -4% | 5% | 0% | -9% | -46% |
| 24 | -51% | 45% | -4% | -11% | -27% | 10% | 22% | -3% | -9% | 13% | -14% | -6% | -36% |
| 23 | -51% | 7% | -22% | -3% | 0% | 44% | 2% | 47% | -12% | -8% | 241% | 14% | 259% |
| 22 | -37% | 10% | 3% | -31% | 158% | 44% | 0% | 12% | -75% | 8% | 0% | -4% | 89% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$710.25M
P/E ratio
—
52W high
$11.61
52W low
$5.87
Volume
62,875
Beta
5.28
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Gyre Therapeutics, Inc. share price today?
- Gyre Therapeutics, Inc. (GYRE) last traded around $5.96 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GYRE have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GYRE. Download the app for real-time alerts.
- How can I analyze Gyre Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.